Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

KPTI

Karyopharm Therapeutics (KPTI)

Karyopharm Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:KPTI
DatumZeitQuelleÜberschriftSymbolFirma
06/03/202522h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
04/03/202522h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
04/03/202522h52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
04/03/202522h51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
04/03/202522h49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
04/03/202522h46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
03/03/202522h05PR Newswire (US)Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KPTIKaryopharm Therapeutics Inc
24/02/202522h16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
24/02/202514h40PR Newswire (US)Karyopharm Announces 1-for-15 Reverse Stock SplitNASDAQ:KPTIKaryopharm Therapeutics Inc
19/02/202522h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
19/02/202513h32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
19/02/202513h30PR Newswire (US)Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
12/02/202515h36Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:KPTIKaryopharm Therapeutics Inc
12/02/202513h00PR Newswire (US)Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025NASDAQ:KPTIKaryopharm Therapeutics Inc
05/02/202522h16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
03/02/202522h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
03/02/202522h05PR Newswire (US)Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KPTIKaryopharm Therapeutics Inc
31/01/202522h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
30/01/202522h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
13/01/202514h34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
13/01/202514h30PR Newswire (US)Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 ObjectivesNASDAQ:KPTIKaryopharm Therapeutics Inc
07/01/202522h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
06/01/202523h07Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
02/01/202522h05PR Newswire (US)Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KPTIKaryopharm Therapeutics Inc
02/01/202513h08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
02/01/202513h00PR Newswire (US)Karyopharm Announces the Appointment of Lori Macomber as Chief Financial OfficerNASDAQ:KPTIKaryopharm Therapeutics Inc
16/12/202422h00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:KPTIKaryopharm Therapeutics Inc
09/12/202414h00PR Newswire (US)Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate CommunicationsNASDAQ:KPTIKaryopharm Therapeutics Inc
05/12/202422h35Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:KPTIKaryopharm Therapeutics Inc
05/12/202422h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KPTI

Kürzlich von Ihnen besucht

Delayed Upgrade Clock